PT3296407T - Mutações do gene pik3ca em cancros humanos - Google Patents

Mutações do gene pik3ca em cancros humanos

Info

Publication number
PT3296407T
PT3296407T PT17197306T PT17197306T PT3296407T PT 3296407 T PT3296407 T PT 3296407T PT 17197306 T PT17197306 T PT 17197306T PT 17197306 T PT17197306 T PT 17197306T PT 3296407 T PT3296407 T PT 3296407T
Authority
PT
Portugal
Prior art keywords
mutations
human cancers
pik3ca gene
pik3ca
gene
Prior art date
Application number
PT17197306T
Other languages
English (en)
Inventor
Vogelstein Bert
Samuels Yardena
Velculescu Victor
Kinzler Kenneth
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3296407(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of PT3296407T publication Critical patent/PT3296407T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PT17197306T 2004-03-02 2005-02-18 Mutações do gene pik3ca em cancros humanos PT3296407T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54888604P 2004-03-02 2004-03-02

Publications (1)

Publication Number Publication Date
PT3296407T true PT3296407T (pt) 2019-08-23

Family

ID=35056655

Family Applications (3)

Application Number Title Priority Date Filing Date
PT191756063T PT3556866T (pt) 2004-03-02 2005-02-18 Mutações do gene de pik3ca em cancros humanos
PT17197306T PT3296407T (pt) 2004-03-02 2005-02-18 Mutações do gene pik3ca em cancros humanos
PT57232779T PT1730303E (pt) 2004-03-02 2005-02-18 Mutações do gene pik3ca em cancros humanos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT191756063T PT3556866T (pt) 2004-03-02 2005-02-18 Mutações do gene de pik3ca em cancros humanos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT57232779T PT1730303E (pt) 2004-03-02 2005-02-18 Mutações do gene pik3ca em cancros humanos

Country Status (14)

Country Link
US (6) US8026053B2 (pt)
EP (5) EP2497836B1 (pt)
JP (10) JP2007530017A (pt)
AU (2) AU2005227148B2 (pt)
CA (1) CA2560696C (pt)
CY (1) CY1121975T1 (pt)
DK (3) DK1730303T3 (pt)
ES (5) ES2537633T3 (pt)
HU (1) HUE045690T2 (pt)
LT (1) LT3296407T (pt)
PL (2) PL1730303T3 (pt)
PT (3) PT3556866T (pt)
SI (2) SI1730303T1 (pt)
WO (1) WO2005091849A2 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE045690T2 (hu) 2004-03-02 2020-01-28 Univ Johns Hopkins A PIK3CA gén mutációi humán rákokban
EP1849877A1 (en) * 2006-04-24 2007-10-31 Erasmus University Medical Center Rotterdam Replicative history of T-and B-cell subsets
WO2008109375A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof
GB2453173A (en) * 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
EP2225376B1 (en) 2007-12-03 2014-01-08 Santaris Pharma A/S Rna antagonist compounds for the modulation of pik3ca expression
WO2009152346A2 (en) * 2008-06-11 2009-12-17 Intradigm Corporation Compositions comprising phosphoinositide 3-kinase sirna and methods of use thereof
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
CA2790416C (en) 2010-03-26 2017-05-23 Mayo Foundation For Medical Education And Research Methods and materials for detecting colorectal neoplasm
AU2011329180A1 (en) * 2010-11-15 2013-05-02 Enzon Pharmaceuticals, Inc. Methods of treating cancers with HER3 and PIK3CA antisense oligonucleotides
EP2640468A4 (en) * 2010-11-16 2014-04-16 Glaxosmithkline Ip No 2 Ltd ADMINISTRATIVE AND TREATMENT PROCEDURES
US9157125B2 (en) 2011-02-02 2015-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services GRIN2A mutations and use thereof for the diagnosis of melanoma
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
CN110016499B (zh) 2011-04-15 2023-11-14 约翰·霍普金斯大学 安全测序系统
EP2736325B1 (en) * 2011-07-28 2018-10-10 F.Hoffmann-La Roche Ag Pik3ca h1047r knock-in non-human animal breast cancer model
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
CN102816839A (zh) * 2012-07-06 2012-12-12 杭州艾迪康医学检验中心有限公司 用于检测结直肠癌pik3ca基因热点突变位点的试剂盒
ES2701742T3 (es) 2012-10-29 2019-02-25 Univ Johns Hopkins Prueba de Papanicolaou para cánceres de ovario y de endometrio
CN105229171A (zh) * 2013-03-13 2016-01-06 豪夫迈·罗氏有限公司 在人pi3kca (pik3ca)基因中检测突变的方法和组合物
US9994911B2 (en) 2013-03-14 2018-06-12 Mayo Foundation For Medical Education And Research Detecting neoplasm
KR101501826B1 (ko) * 2013-04-05 2015-03-13 연세대학교 산학협력단 위암에 대한 예후 예측 모형의 제조방법
WO2015017528A1 (en) * 2013-07-30 2015-02-05 Blueprint Medicines Corporation Pik3c2g fusions
ES2812753T3 (es) 2014-03-31 2021-03-18 Mayo Found Medical Education & Res Detección de neoplasma colorectal
CN106715723B (zh) * 2014-08-07 2021-03-30 法马西斯特有限责任公司 测定样品中pik3ca突变状态的方法
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
CN104531854B (zh) * 2014-11-10 2017-01-18 中国人民解放军第三〇七医院 检测西妥昔单抗治疗转移性结直肠癌耐药的试剂盒
US10030272B2 (en) 2015-02-27 2018-07-24 Mayo Foundation For Medical Education And Research Detecting gastrointestinal neoplasms
US10435755B2 (en) 2015-03-27 2019-10-08 Exact Sciences Development Company, Llc Detecting esophageal disorders
CA3235175A1 (en) 2015-05-27 2016-12-01 Quest Diagnostics Investments Incorporated Compositions and methods for screening solid tumors
WO2017027653A1 (en) 2015-08-11 2017-02-16 The Johns Hopkins University Assaying ovarian cyst fluid
US10006093B2 (en) 2015-08-31 2018-06-26 Mayo Foundation For Medical Education And Research Detecting gastric neoplasm
EP3383391A1 (en) 2015-12-03 2018-10-10 Novartis AG Treatment of cancer with a pi3k inhibitor in a patient preselected for having a pik3ca mutation in the ctdna
RU2608960C1 (ru) * 2016-03-18 2017-01-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "РОНЦ им. Н.Н. Блохина" Минздрава России) Клеточная линия crov Cel муцинозного рака яичников человека, предназначенная для разработки лечения таргетными препаратами
US10370726B2 (en) 2016-04-14 2019-08-06 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasia
KR102380690B1 (ko) 2016-04-14 2022-03-29 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 췌장 고도 이형성증의 검출방법
CN118147307A (zh) 2017-02-28 2024-06-07 梅约医学教育与研究基金会 用于表征来自人患者的样品的方法
WO2018181863A1 (ja) * 2017-03-30 2018-10-04 国立大学法人東京大学 異なる複数の目的遺伝子の評価方法
JP7067896B2 (ja) 2017-10-27 2022-05-16 シスメックス株式会社 品質評価方法、品質評価装置、プログラム、および記録媒体
EP3717644A4 (en) 2017-11-30 2021-12-29 Mayo Foundation for Medical Education and Research Detecting breast cancer
CN111363827A (zh) * 2020-04-30 2020-07-03 北京和合医学诊断技术股份有限公司 用于检测pik3ca基因突变的引物组及其应用方法
DE102021126650A1 (de) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff
CN116219015A (zh) * 2023-02-06 2023-06-06 中日友好医院(中日友好临床医学研究所) 基于pcr的dna中pik3ca基因突变检测试剂盒及检测方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248671A (en) * 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5846824A (en) * 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5846624A (en) * 1996-12-06 1998-12-08 The Standard Register Company Dual face pressure sensitive label
US7670767B1 (en) 1997-01-16 2010-03-02 The Regents Of The University Of California Genetic alterations associated with cancer
US6277563B1 (en) 1997-01-16 2001-08-21 The Regents Of The University Of California Genetic alterations associated with cancer
US6558903B1 (en) 1999-06-30 2003-05-06 Millennium Pharmaceuticals, Inc. Kinases and uses thereof
ES2302699T3 (es) * 1999-08-27 2008-08-01 Novartis Vaccines And Diagnostics, Inc. Oligonucleotidos quimericos antisentido y formulaciones de transfeccion celular de los mismos.
WO2001055208A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2002027028A1 (en) * 2000-09-28 2002-04-04 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
US20020142305A1 (en) 2001-03-27 2002-10-03 Koei Chin Methods for diagnosing and monitoring ovarian cancer by screening gene copy numbers
US20030135033A1 (en) * 2002-01-04 2003-07-17 Anke Klippel-Giese Compounds and methods for the identification and/ or validation of a target
WO2004010900A1 (en) 2002-07-25 2004-02-05 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
NZ542475A (en) * 2003-04-03 2009-04-30 Semafore Pharmaceuticals Inc PI-3 kinase inhibitor prodrugs
HUE045690T2 (hu) 2004-03-02 2020-01-28 Univ Johns Hopkins A PIK3CA gén mutációi humán rákokban

Also Published As

Publication number Publication date
PL1730303T3 (pl) 2014-04-30
PT3556866T (pt) 2021-04-30
CA2560696C (en) 2019-06-25
EP1730303B1 (en) 2013-07-31
JP2013226141A (ja) 2013-11-07
JP2007530017A (ja) 2007-11-01
SI3296407T1 (sl) 2019-09-30
HUE045690T2 (hu) 2020-01-28
US20110319477A1 (en) 2011-12-29
EP2896703A3 (en) 2015-10-21
JP7169315B2 (ja) 2022-11-10
EP1730303A4 (en) 2009-09-09
US10704105B2 (en) 2020-07-07
JP2012183065A (ja) 2012-09-27
EP2896703B1 (en) 2017-10-25
CY1121975T1 (el) 2020-10-14
LT3296407T (lt) 2019-09-10
US20200248275A1 (en) 2020-08-06
US8026053B2 (en) 2011-09-27
DK3556866T3 (da) 2021-05-03
AU2005227148A1 (en) 2005-10-06
EP2497836A1 (en) 2012-09-12
ES2437590T3 (es) 2014-01-13
JP2020092711A (ja) 2020-06-18
DK1730303T3 (da) 2013-11-04
JP6694543B2 (ja) 2020-05-13
ES2869167T8 (es) 2022-01-20
AU2011200600B2 (en) 2012-02-23
PL3296407T3 (pl) 2019-11-29
JP5894110B2 (ja) 2016-03-23
EP3296407B1 (en) 2019-05-22
JP2020115891A (ja) 2020-08-06
JP2018023400A (ja) 2018-02-15
DK3296407T3 (da) 2019-08-19
US20090208505A1 (en) 2009-08-20
WO2005091849A3 (en) 2009-04-16
JP7001735B2 (ja) 2022-02-10
EP3296407A1 (en) 2018-03-21
JP6695381B2 (ja) 2020-05-20
AU2011200600A1 (en) 2011-03-10
EP3556866A1 (en) 2019-10-23
US20150079593A1 (en) 2015-03-19
PT1730303E (pt) 2013-10-31
JP2022059046A (ja) 2022-04-12
JP6250017B2 (ja) 2017-12-20
JP2016041078A (ja) 2016-03-31
US10787713B2 (en) 2020-09-29
US10422006B2 (en) 2019-09-24
JP5336620B2 (ja) 2013-11-06
WO2005091849A2 (en) 2005-10-06
US20200024671A1 (en) 2020-01-23
EP2896703A2 (en) 2015-07-22
US11549150B2 (en) 2023-01-10
US20180119231A1 (en) 2018-05-03
ES2743125T3 (es) 2020-02-18
AU2005227148B2 (en) 2010-11-11
JP2018153189A (ja) 2018-10-04
ES2869167T3 (es) 2021-10-25
EP2497836B1 (en) 2015-01-14
ES2663248T3 (es) 2018-04-11
JP2020028300A (ja) 2020-02-27
EP3556866B1 (en) 2021-04-07
SI1730303T1 (sl) 2013-12-31
EP1730303A2 (en) 2006-12-13
JP6395917B2 (ja) 2018-09-26
CA2560696A1 (en) 2005-10-06
ES2537633T3 (es) 2015-06-10
JP7304987B2 (ja) 2023-07-07

Similar Documents

Publication Publication Date Title
LT3296407T (lt) Pik3ca geno mutacijos žmonių navikuose
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
IL177847A0 (en) Use of lipid conjugates in the treatment of disease
IL173576A0 (en) Use of polypeptides of the cupredoxin family in cancer therapy
EP1814909A4 (en) USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP1747284A4 (en) DIAGNOSTICS AND THERAPEUTICS OF CANCER
IL172316A0 (en) Novel compounds and their use in therapy
EP1838330A4 (en) TREATMENT OF SOLID TUMORS
ZA200703699B (en) Nitrobenzindoles and their use in cancer therapy
GB0418328D0 (en) Cancer methods and medicaments
TWI368509B (en) Antituberculous therapeutic drugs and kit containing the same
HK1105886A1 (en) Pharmaceutical compositions comprising l-733060 for use in the treatment of cancer tumours l-733060
IL212215A0 (en) Use of lipid conjugates in the treatment of disease
EP1757282A4 (en) USE OF KAURANE COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS
GB0326578D0 (en) Cancer diagnosis and therapy
EP1666046A4 (en) USE OF N-ACETYL-D-AMINOGLYCOSAMINE FOR THE PREPARATION OF DRUGS FOR THE TREATMENT OF CANCER AND METASTASES
IL185575A0 (en) Benzoxazocines and their therapeutic use
IL175774A0 (en) Use of siramesine in the treatment of cancer
EP1907855A4 (en) GENETIC AND EPIGENETIC MODIFICATIONS IN THE DIAGNOSIS AND TREATMENT OF CANCER
GB2424794B (en) Improvements in the use of pre-configuration
IL229982A0 (en) Use of fatty conjugates to treat diseases
IL229980A0 (en) Use of fatty conjugates to treat diseases
IL229981A0 (en) Use of fatty conjugates to treat diseases
GB0421917D0 (en) Cancer diagnosis and therapy
GB0423423D0 (en) Improvements in the design of toothbrushes